

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Novel Nucleotide Analogues as Potential Substrates for TMPK, a Key Enzyme in the Metabolism of AZT

H. C. Müller^a; C. Meier^{ab}; J. Balzarini^c; J. Reinstein^d

^a Institute of Organic Chemistry, University of Hamburg, Hamburg, Germany ^b Institut für Organische Chemie, Universität Hamburg, Hamburg, Germany ^c Rega Institute for Medical Research, Katholieke Universiteit, Leuven, Belgium ^d Department of Physical Biochemistry, Max Planck Institute for Molecular Physiology, Dortmund, Germany

Online publication date: 09 August 2003

To cite this Article Müller, H. C. , Meier, C. , Balzarini, J. and Reinstein, J.(2003) 'Novel Nucleotide Analogues as Potential Substrates for TMPK, a Key Enzyme in the Metabolism of AZT', *Nucleosides, Nucleotides and Nucleic Acids*, 22: 5, 821 — 823

To link to this Article: DOI: 10.1081/NCN-120022662

URL: <http://dx.doi.org/10.1081/NCN-120022662>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Novel Nucleotide Analogues as Potential Substrates for TMPK, a Key Enzyme in the Metabolism of AZT

H. C. Müller,¹ C. Meier,^{1,*} J. Balzarini,² and J. Reinstein³

¹Institute of Organic Chemistry, University of Hamburg, Hamburg, Germany

²Rega Institute for Medical Research, Katholieke Universiteit, Leuven, Belgium

³Max Planck Institute for Molecular Physiology, Department of Physical
Biochemistry, Dortmund, Germany

ABSTRACT

Novel cyclic and acyclic analogues of dTMP and AZTMP were synthesized from the corresponding *cyclo*Sal-phosphotriesters. This method yielded the nucleotides in good yields with a simple work-up. Investigation of the substrate properties of the modified nucleotides towards TmpK showed, that they are very poor substrates for this key enzyme in the bioactivation of AZT.

INTRODUCTION

Nucleoside-based inhibitors of reverse transcriptase were the first drugs to be used in the chemotherapy of AIDS. After entering the cell, these substances have to be activated to their triphosphates by cellular kinases. Thus, for the most extensively used drug AZT, the product of the initial phosphorylation is a very poor

*Correspondence: C. Meier, Institut für Organische Chemie, Universität Hamburg, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany; Fax: +49 404 2838 2495; E-mail: chris.meier@chemie.uni-hamburg.de.





substrate for the second kinase, thymidylate kinase (TpmK). The steric demand of the azido-group in the 3'-position of AZTMP causes the so-called P-loop repulsion and therefore a 200-fold decrease in the rate of phosphorylation.^[1] Here, we present the syntheses of novel analogues of dTMP and AZTMP as potential substrates of TpmK by hydrolysis of the corresponding *cyclo*Sal-phosphotriesters^[2] on a preparative scale.

RESULTS

Since *cyclo*Sal-phosphotriesters have been designed to selectively deliver nucleoside monophosphates (NMPs) by means of chemical hydrolysis, these compounds can be used as synthons in the synthesis of NMPs. The *cyclo*Sal-nucleoside monophosphates were synthesized directly from the corresponding nucleoside analogues following either the chlorophosphite- or the phosphoramidite-approach.^[2] The phosphotriesters were then hydrolysed by treatment with triethylamine in acetonitrile/water. The work up consisted of reversed-phase chromatography followed by ion exchange. The work up was very simple since no polar side-products are formed. This method yields the monophosphates in high yields (up to 74%).

The evaluation of the substrate properties of the NMPs towards TpmK showed, that the cyclic nucleotides **3–5** are hardly phosphorylated by TpmK at all, although the substituents were very similar or even isoster to the azido-group in AZTMP **2**. This might be explained by the fact, that these substituents lack the zwitter-ionic structure of the azido-group. In contrast to suggestions from molecular modelling experiments,^[1] the acyclic nucleotides **6–8** were also poor substrates for TpmK,

Table 1. Steady-state kinetics of nucleotides **1–8** with human TpmK.

<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>1 - 5</p> </div> <div style="text-align: center;">  <p>6 - 8</p> </div> </div>					
NMP	R	X	$k_{\text{cat}}[\text{s}^{-1}]^{\text{a}}$	$K_{\text{M}}[\mu\text{M}]^{\text{b}}$	$k_{\text{cat}}/K_{\text{M}}[\text{M}^{-1}\text{s}^{-1}10^{-3}]$
1	OH	—	≈ 0.73	6 ± 1	122 ± 22
2	N ₃	—	≈ 0.0122	12 ± 3	1.0 ± 0.2
3	SCN	—	< 0.02	Not detectable	Not detectable
4	CH ₂ CHCH ₂	—	< 0.02	Not detectable	Not detectable
5	CH ₂ CCH	—	< 0.02	Not detectable	Not detectable
6	OH	O	≈ 0.008	≈ 1300	≈ 0.006
7	OH	CH ₂	≈ 0.0014	≈ 20	≈ 0.07
8	N ₃	CH ₂	Not detectable	Not detectable	Not detectable

^aCatalytic rate at substrate saturation.

^bMichaelis constant.

caused possibly by entropic effects. However, compound **6**, which has both the aminor oxygen and the free hydroxy-group of the natural substrate dTMP **1**, shows a higher rate of phosphorylation than compound **7**, which lacks the aminor oxygen. Compound **8**, having no aminor oxygen and the azido-group instead of the hydroxy-group is hardly phosphorylated at all. Table 1 summarizes the enzyme kinetical data.

REFERENCES

1. Lavie, A.; Schlichting, I.; Vetter, I.R.; Konrad, M.; Reinstein, J.; Goody, R.S. The bottleneck in AZT activation. *Nature Medicine* **1997**, 3, 922–924.
2. Meier, C. *cycloSal*-pronucleotides—design of chemical trojan horses. *Mini Reviews Med. Chem.* **2002**, 2, 219–234.



